David Lacey, MD
Chairman, Scientific Advisory Board

Dr. Lacey was the former research head at Amgen Inc. He played a fundamental role in the discovery of the OPG/RANKL/RANK pathway at Amgen which led to the development of the anti-RANKL human mAb denosumab, an emerging dual blockbuster for both osteoporosis and cancer-related bone diseases. Denosumab has received a number of awards including the US 2011 Prix Galien award for best new biotechnology product and the 2010 Scrip award for best new drug.
Senior Vice President, Discovery Research and Amgen South San Francisco Site Leader, Vice President, Basic Research, Metabolic Disorders, Amgen Inc. (2000-2011).
Senior Director, Department of Pathology/Pathology, Amgen Inc. (1994-2000) Assistant Professor of Pathology, Jewish Washington University Medical Center M.D. University of Colorado.
Lars-Birgerson, M.D., Ph.D.
Advisor, Scientific Advisory Board

Lars Birgerson, M.D., Ph.D. is a physician with more than 25 years of biopharmaceutical industry experience in senior positions. He is a well-recognized global authority and expert. He has built and led Global and US functions integrating Medical and Health Economics Outcomes Research for several leading companies, including Bristol-Myers Squibb, Genentech, Roche, and Pharmacia.
Lars received his M.D., Ph.D. and completed residencies in Obstetrics and Gynecology, General Surgery, Gynecological Oncology, and Urological Surgery at Uppsala University in Sweden.
Mark Hallett M.D.
Advisor, Scientific Advisory Board

Dr. Hallett is the Chief of the Human Motor Control Section, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland. His work mainly deals with principles of motor control and the pathophysiology of movement disorders, including brain plasticity and its relevance to neurological disorders and the pathophysiology of Dystonia, Parkinsoní»s Disease, and Myoclonus. Recently he became interested in disorders of volition, including tic and psychogenic movement disorders.
Dr. Hallett received his M.D. at Harvard University, interned at the Peter Bent Brigham Hospital and trained in Neurology at Massachusetts General Hospital.
Ada H.C. Kung, Ph.D., DABT
Advisor, Scientific Advisory Board

Dr Kung is an American Board of Toxicology certified toxicologist (DABT) with over 30 years of toxicology, pharmacokinetics, pharmacodynamics and regulatory experience. She founded Expedient Solutions International (ESI) in 2015 to provide consulting services for companies in China, Taiwan, and USA in the translational medicine to bring drug candidates from discovery to development to clinical trials. She has wholly overseen or involved in the submission of several INDs/NDAs/BLAs for small molecule drugs, cytokine and monoclonal antibody therapeutics and botanical products. Prior to founding ESI Dr. Kung was the co-founder of Bridge Laboratories (now Pharmaron) in China and had held various executive positions in the pharmaceutical industry in the USA. Dr. Kung received her Ph.D. from Ohio State University.